Nipro Vialex – 26th January 2025
PCI – 7th June 2024
Temax_Krautz

Current Edition

Nasal & Pulmonary Drug Development
Novo Nordisk 20 March 2024, 11:21
Carterra – 24th March 2025

Adaptive Licensing – Maximising Value

Adaptive licensing is currently being promoted as a means for earlier patient access to novel drugs. However, there is a high level of uncertainty regarding the current regulatory feasibility of certain adaptive licensing strategies and the potential commercial advantages of such strategies. Daniel Lewinski and Christian Elze at Catenion explains the current EU and US regulatory frameworks and a methodology to assess the commercial implications of adaptive licensing strategies.
https://international-pharma.com/wp-content/uploads/2014/01/Adaptive.1.pdf

Scott Pharma – 25.03.2025
SMI – 24/03/2025
Chemspec Europe – 27.02.2025
PHARMAP: Mon 14 October 2024, 10.36
FujiFilm Skyscraper: 26th November 2024
Woolcool 26 March 2024, 16:16
Biopharma group 6 March 2024, 09:40
EyeC 18 March 2024, 13:10
L.B. Bohle – 08.04.2025